Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Orgenesis Inc (ORGS) USD0.0001

Sell:$4.80 Buy:$4.89 Change: $0.14 (2.79%)
Market closed |  Prices as at close on 28 September 2021 | Switch to live prices |
Sell:$4.80
Buy:$4.89
Change: $0.14 (2.79%)
Market closed |  Prices as at close on 28 September 2021 | Switch to live prices |
Sell:$4.80
Buy:$4.89
Change: $0.14 (2.79%)
Market closed |  Prices as at close on 28 September 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Orgenesis Inc. is a biotech company operating to unlock the potential of cell and gene therapies (CGTs). The Company is focused on autologous (using the patient’s own cells) therapies with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment. The Company has developed a Point of Care Platform comprised of three components: POCare Therapies, POCare Technologies and POCare Network. Its therapeutic portfolio pipeline is diverse and addresses various clinical needs. POCare Technology uses automated systems across a collaborative POCare Network via a combination of science, technology, engineering and networking.

Contact details

Address:
20271 Goldenrod Ln
GERMANTOWN
20876-4064
United States
Telephone:
+1 (480) 6596404
Website:
https://www.orgenesis.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ORGS
ISIN:
US68619K2042
Market cap:
$121.46 million
Shares in issue:
24.54 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Vered Caplan
    Chairperson of the Board of Directors, Chief Executive Officer
  • Neil Reithinger
    Chief Financial Officer, Treasurer, Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.